Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.60 |
| ▸ | MAPK13 | O15264 | 3/20 | 0.51 |
| ▸ | MAPK12 | P53778 | 3/20 | 0.51 |
| ▸ | MAPK11 | Q15759 | 3/20 | 0.51 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.51 |
| ▸ | RAF1 | P04049 | 1/20 | 0.51 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.47 |
| ▸ | GCGR | P47871 | 1/20 | 0.47 |
| ▸ | NOX1 | Q9Y5S8 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 4/20 | 0.45 |
| ▸ | TP53 | P04637 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11180276 | 0.84 | NOX1 (0.57) | PDE10AMAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL10969806 | 0.83 | MAPK14 (0.49) | PDE10AMAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL10971251 | 0.80 | NOX1 (0.54) | PDE10AMAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL10965277 | 0.79 | MAPK13 (0.59) | PDE10AMAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL10968539 | 0.79 | PDE10A (0.50) | PDE10AMAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL10970388 | 0.78 | MAPK13 (0.54) | PDE10AMAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL10970147 | 0.78 | MAPK14 (0.61) | PDE10AMAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL10814349 | 0.78 | NOX1 (0.57) | PDE10AMAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL11272419 | 0.77 | ALDH1A1 (0.66) | PDE10AMAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL9255839 | 0.76 | MAPT (0.43) | PDE10AALOX5MAPTMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20010047038-A1 | Method of using (H+/K+) ATPase inhibitors as antiviral agents | MOORMAN ALAN E (US) | 2001-11-29 | — | — | US | claimed |
| US-5945425-A | ADENOSINE TRIPHOSPHASE INHIBITOR; DNA VIRICIDE | G.D. SEARLE & CO. (US) | 1999-08-31 | — | — | US | claimed |
| EP-0043788-B1 | IMIDAZOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR PHARMACEUTICAL COMPOSITIONS | SCHERING AKTIENGESELLSCHAFT (DE) | 1985-10-30 | — | — | EP | claimed |
| US-4402960-A | Antiinflammatory imidazole derivatives | SCHERING AKTIENGESELLSCHAFT (DE) | 1983-09-06 | — | — | US | claimed |
| EP-0043788-A1 | Imidazole derivatives, process for their preparation and their pharmaceutical compositions | SCHERING AKTIENGESELLSCHAFT (DE) | 1982-01-13 | — | — | EP | claimed |
| US-6906078-B2 | Method of using (H+/K+) ATPase inhibitors as antiviral agents | PHARMACIA CORPORATION (US) | 2005-06-14 | — | — | US | disclosed |
| US-20010047038-A1 | Method of using (H+/K+) ATPase inhibitors as antiviral agents | MOORMAN ALAN E (US) | 2001-11-29 | — | — | US | disclosed |
| US-5945425-A | ADENOSINE TRIPHOSPHASE INHIBITOR; DNA VIRICIDE | G.D. SEARLE & CO. (US) | 1999-08-31 | — | — | US | disclosed |
| EP-0043788-B1 | IMIDAZOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR PHARMACEUTICAL COMPOSITIONS | SCHERING AKTIENGESELLSCHAFT (DE) | 1985-10-30 | — | — | EP | disclosed |
| US-4528298-A | Antiinflammatory imidazole derivatives | SCHERING AKTIENGESELLSCHAFT (DE) | 1985-07-09 | — | — | US | disclosed |
| US-4402960-A | Antiinflammatory imidazole derivatives | SCHERING AKTIENGESELLSCHAFT (DE) | 1983-09-06 | — | — | US | disclosed |
| EP-0043788-A1 | Imidazole derivatives, process for their preparation and their pharmaceutical compositions | SCHERING AKTIENGESELLSCHAFT (DE) | 1982-01-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010047038-A1 | Method of using (H+/K+) ATPase inhibitors as antiviral agents | ATP4A, ATP1A1, ATP1A4 | PDE10A 2112/4885MAPK13 1836/4885MAPK12 2073/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.